We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Gleevec Maker Immune From Antitrust Liability, 1st Circuit Affirms

Mealey's (August 24, 2018, 11:41 AM EDT) -- BOSTON — Allegations by two putative classes that Novartis Pharmaceuticals Corp. fraudulently procured a patent for the leukemia drug Gleevec are not plausible, and the drug maker thus cannot be subject...
To view the full article, register now.